BIOMAT Database Logo BIOMAT Database Logo

Micro-encapsulated secretory leukocyte protease inhibitor decreases cell-mediated immune response in autoimmune orchitis. 2011

Vanesa Anabella Guazzone, and Diego Guerrieri, and Patricia Jacobo, and Romina Julieta Glisoni, and Diego Chiappetta, and Livia Lustig, and H Eduardo Chuluyan
Instituto de Investigaciones en Reproducción, Universidad de Buenos Aires, Argentina.

OBJECTIVE We previously reported that recombinant human Secretory Leukocyte Protease Inhibitor (SLPI) inhibits mitogen-induced proliferation of human peripheral blood mononuclear cells. To determine the relevance of this effect in vivo, we investigated the immuno-regulatory role of SLPI in an experimental autoimmune orchitis (EAO) model. METHODS In order to increase SLPI half life, poly-ε-caprolactone microspheres containing SLPI were prepared and used for in vitro and in vivo experiments. Multifocal orchitis was induced in Sprague-Dawley adult rats by active immunization with testis homogenate and adjuvants. Microspheres containing SLPI (SLPI group) or vehicle (control group) were administered s.c. to rats during or after the immunization period. RESULTS In vitro SLPI-release microspheres inhibited rat lymphocyte proliferation and retained trypsin inhibitory activity. A significant decrease in EAO incidence was observed in the SLPI group (37.5%) versus the control group (93%). Also, SLPI treatment significantly reduced severity of the disease (mean EAO score: control, 6.33±0.81; SLPI, 2.72±1.05). In vivo delayed-type hypersensitivity and ex vivo proliferative response to testicular antigens were reduced by SLPI treatment compared to control group (p<0.05). CONCLUSIONS Our results highlight the in vivo immunosuppressive effect of released SLPI from microspheres which suggests its feasible therapeutic use.

UI MeSH Term Description Entries
D006968 Hypersensitivity, Delayed An increased reactivity to specific antigens mediated not by antibodies but by sensitized T CELLS. Hypersensitivity, Tuberculin-Type,Hypersensitivity, Type IV,Tuberculin-Type Hypersensitivity,Type IV Hypersensitivity,Delayed Hypersensitivity,Delayed Hypersensitivities,Hypersensitivity, Tuberculin Type,Tuberculin Type Hypersensitivity,Tuberculin-Type Hypersensitivities,Type IV Hypersensitivities
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008297 Male Males
D008863 Microspheres Small uniformly-sized spherical particles, of micrometer dimensions, frequently labeled with radioisotopes or various reagents acting as tags or markers. Latex Beads,Latex Particles,Latex Spheres,Microbeads,Bead, Latex,Beads, Latex,Latex Bead,Latex Particle,Latex Sphere,Microbead,Microsphere,Particle, Latex,Particles, Latex,Sphere, Latex,Spheres, Latex
D009920 Orchitis Inflammation of a TESTIS. It has many features of EPIDIDYMITIS, such as swollen SCROTUM; PAIN; PYURIA; and FEVER. It is usually related to infections in the URINARY TRACT, which likely spread to the EPIDIDYMIS and then the TESTIS through either the VAS DEFERENS or the lymphatics of the SPERMATIC CORD. Orchitides
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal

Related Publications

Vanesa Anabella Guazzone, and Diego Guerrieri, and Patricia Jacobo, and Romina Julieta Glisoni, and Diego Chiappetta, and Livia Lustig, and H Eduardo Chuluyan
Secretory leukocyte protease inhibitor in cancer development.
December 2004, Annals of the New York Academy of Sciences,
Vanesa Anabella Guazzone, and Diego Guerrieri, and Patricia Jacobo, and Romina Julieta Glisoni, and Diego Chiappetta, and Livia Lustig, and H Eduardo Chuluyan
Secretory leukocyte protease inhibitor in cystic fibrosis.
January 1993, Agents and actions. Supplements,
Vanesa Anabella Guazzone, and Diego Guerrieri, and Patricia Jacobo, and Romina Julieta Glisoni, and Diego Chiappetta, and Livia Lustig, and H Eduardo Chuluyan
Secretory leukocyte protease inhibitor inhibits neutrophil apoptosis.
February 2011, Respirology (Carlton, Vic.),
Vanesa Anabella Guazzone, and Diego Guerrieri, and Patricia Jacobo, and Romina Julieta Glisoni, and Diego Chiappetta, and Livia Lustig, and H Eduardo Chuluyan
Secretory leukocyte protease inhibitor is a novel inhibitor of fibroblast-mediated collagen gel contraction.
April 2000, Experimental cell research,
Vanesa Anabella Guazzone, and Diego Guerrieri, and Patricia Jacobo, and Romina Julieta Glisoni, and Diego Chiappetta, and Livia Lustig, and H Eduardo Chuluyan
Plasma secretory leukocyte protease inhibitor in febrile patients.
July 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
Vanesa Anabella Guazzone, and Diego Guerrieri, and Patricia Jacobo, and Romina Julieta Glisoni, and Diego Chiappetta, and Livia Lustig, and H Eduardo Chuluyan
Secretory leukocyte protease inhibitor regulates nerve reflex-mediated skin barrier function in psoriasis.
August 2022, Journal of the European Academy of Dermatology and Venereology : JEADV,
Vanesa Anabella Guazzone, and Diego Guerrieri, and Patricia Jacobo, and Romina Julieta Glisoni, and Diego Chiappetta, and Livia Lustig, and H Eduardo Chuluyan
Differential inhibition of mast cell chymases by secretory leukocyte protease inhibitor.
January 1998, Biochimica et biophysica acta,
Vanesa Anabella Guazzone, and Diego Guerrieri, and Patricia Jacobo, and Romina Julieta Glisoni, and Diego Chiappetta, and Livia Lustig, and H Eduardo Chuluyan
Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism.
October 2008, Journal of virology,
Vanesa Anabella Guazzone, and Diego Guerrieri, and Patricia Jacobo, and Romina Julieta Glisoni, and Diego Chiappetta, and Livia Lustig, and H Eduardo Chuluyan
Secretory leukocyte protease inhibitor (SLPI), a multifunctional protein in the host defense response.
April 2016, Cytokine & growth factor reviews,
Vanesa Anabella Guazzone, and Diego Guerrieri, and Patricia Jacobo, and Romina Julieta Glisoni, and Diego Chiappetta, and Livia Lustig, and H Eduardo Chuluyan
Functional studies of human secretory leukocyte protease inhibitor.
January 1988, Advances in experimental medicine and biology,
Copied contents to your clipboard!